Clinical Pharmacokinetics of Zidovudine: An Update

Edward P. Acosta, Linda M. Page, Courtney V. Fletcher

Research output: Contribution to journalReview article

63 Citations (Scopus)

Abstract

The battle against the acquired immune deficiency syndrome (AIDS) is now into its second decade, and substantial advancements have been made in our understanding of the complex life cycle of, and the immunopathology associated with, human immunodeficiency virus (HIV) infection, as well as of the drugs used to modify the course of disease. Zidovudine was the first agent approved for treatment of HIV disease, and since its widespread availability in 1987 the pharmacokinetic disposition and clinical effects of zidovudine have been extensively evaluated. This article reviews the absorption, distribution, metabolism and elimination characteristics of zidovudine, focusing on more recent information. In addition, factors that may or may not affect zidovudine disposition are discussed. These include selected drug interactions and concomitant disease states such as renal and hepatic insufficiency. Issues such as bodyweight normalisation, maternal-fetal transfer, pregnancy and intracellular phosphorylation are discussed in relation to the pharmacokinetics and clinical efficacy of zidovudine. Finally, information regarding the clinical pharmacodynamics of zidovudine is presented. This includes possible relationships between zidovudine pharmacokinetics and markers of efficacy and toxicity, and the significance of linking pharmacokinetic and pharmacodynamic information.

Original languageEnglish (US)
Pages (from-to)251-262
Number of pages12
JournalClinical Pharmacokinetics
Volume30
Issue number4
DOIs
StatePublished - Jan 1 1996

Fingerprint

Zidovudine
Pharmacokinetics
Virus Diseases
HIV
Hepatic Insufficiency
Life Cycle Stages
Drug Interactions
Renal Insufficiency
Acquired Immunodeficiency Syndrome
Phosphorylation
Mothers
Pregnancy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical Pharmacokinetics of Zidovudine : An Update. / Acosta, Edward P.; Page, Linda M.; Fletcher, Courtney V.

In: Clinical Pharmacokinetics, Vol. 30, No. 4, 01.01.1996, p. 251-262.

Research output: Contribution to journalReview article

Acosta, Edward P. ; Page, Linda M. ; Fletcher, Courtney V. / Clinical Pharmacokinetics of Zidovudine : An Update. In: Clinical Pharmacokinetics. 1996 ; Vol. 30, No. 4. pp. 251-262.
@article{90c805122ef0421bba68a864cb3908be,
title = "Clinical Pharmacokinetics of Zidovudine: An Update",
abstract = "The battle against the acquired immune deficiency syndrome (AIDS) is now into its second decade, and substantial advancements have been made in our understanding of the complex life cycle of, and the immunopathology associated with, human immunodeficiency virus (HIV) infection, as well as of the drugs used to modify the course of disease. Zidovudine was the first agent approved for treatment of HIV disease, and since its widespread availability in 1987 the pharmacokinetic disposition and clinical effects of zidovudine have been extensively evaluated. This article reviews the absorption, distribution, metabolism and elimination characteristics of zidovudine, focusing on more recent information. In addition, factors that may or may not affect zidovudine disposition are discussed. These include selected drug interactions and concomitant disease states such as renal and hepatic insufficiency. Issues such as bodyweight normalisation, maternal-fetal transfer, pregnancy and intracellular phosphorylation are discussed in relation to the pharmacokinetics and clinical efficacy of zidovudine. Finally, information regarding the clinical pharmacodynamics of zidovudine is presented. This includes possible relationships between zidovudine pharmacokinetics and markers of efficacy and toxicity, and the significance of linking pharmacokinetic and pharmacodynamic information.",
author = "Acosta, {Edward P.} and Page, {Linda M.} and Fletcher, {Courtney V.}",
year = "1996",
month = "1",
day = "1",
doi = "10.2165/00003088-199630040-00001",
language = "English (US)",
volume = "30",
pages = "251--262",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Clinical Pharmacokinetics of Zidovudine

T2 - An Update

AU - Acosta, Edward P.

AU - Page, Linda M.

AU - Fletcher, Courtney V.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The battle against the acquired immune deficiency syndrome (AIDS) is now into its second decade, and substantial advancements have been made in our understanding of the complex life cycle of, and the immunopathology associated with, human immunodeficiency virus (HIV) infection, as well as of the drugs used to modify the course of disease. Zidovudine was the first agent approved for treatment of HIV disease, and since its widespread availability in 1987 the pharmacokinetic disposition and clinical effects of zidovudine have been extensively evaluated. This article reviews the absorption, distribution, metabolism and elimination characteristics of zidovudine, focusing on more recent information. In addition, factors that may or may not affect zidovudine disposition are discussed. These include selected drug interactions and concomitant disease states such as renal and hepatic insufficiency. Issues such as bodyweight normalisation, maternal-fetal transfer, pregnancy and intracellular phosphorylation are discussed in relation to the pharmacokinetics and clinical efficacy of zidovudine. Finally, information regarding the clinical pharmacodynamics of zidovudine is presented. This includes possible relationships between zidovudine pharmacokinetics and markers of efficacy and toxicity, and the significance of linking pharmacokinetic and pharmacodynamic information.

AB - The battle against the acquired immune deficiency syndrome (AIDS) is now into its second decade, and substantial advancements have been made in our understanding of the complex life cycle of, and the immunopathology associated with, human immunodeficiency virus (HIV) infection, as well as of the drugs used to modify the course of disease. Zidovudine was the first agent approved for treatment of HIV disease, and since its widespread availability in 1987 the pharmacokinetic disposition and clinical effects of zidovudine have been extensively evaluated. This article reviews the absorption, distribution, metabolism and elimination characteristics of zidovudine, focusing on more recent information. In addition, factors that may or may not affect zidovudine disposition are discussed. These include selected drug interactions and concomitant disease states such as renal and hepatic insufficiency. Issues such as bodyweight normalisation, maternal-fetal transfer, pregnancy and intracellular phosphorylation are discussed in relation to the pharmacokinetics and clinical efficacy of zidovudine. Finally, information regarding the clinical pharmacodynamics of zidovudine is presented. This includes possible relationships between zidovudine pharmacokinetics and markers of efficacy and toxicity, and the significance of linking pharmacokinetic and pharmacodynamic information.

UR - http://www.scopus.com/inward/record.url?scp=0029968585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029968585&partnerID=8YFLogxK

U2 - 10.2165/00003088-199630040-00001

DO - 10.2165/00003088-199630040-00001

M3 - Review article

C2 - 8983858

AN - SCOPUS:0029968585

VL - 30

SP - 251

EP - 262

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 4

ER -